Kyntra Bio Inc
KYNB Healthcare Biotechnology
In the quarter to June 2026, revenue fell 209.4%, EPS grew 257.5% and free cash flow fell 131.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow KYNB
Kyntra Bio Inc (KYNB) Altman Z-score
Kyntra Bio Inc's Altman Z-score for fiscal 2025 is −20.33, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −20.33 | (6.25) |
| FY2024 | −14.08 | (5.99) |
| FY2023 | −8.08 | (5.01) |
| FY2022 | −3.07 | (1.68) |
| FY2021 | −1.39 | (5.24) |
| FY2020 | 3.85 | (2.59) |
| FY2019 | 6.44 | 0.21 |
| FY2018 | 6.23 | 0.69 |
| FY2017 | 5.53 | 3.64 |
| FY2016 | 1.89 | (1.11) |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.58 | — | 0.70 | |
| Retained earnings / total assets | (14.27) | — | −19.97 | |
| EBIT / total assets | (0.38) | — | −1.27 | |
| Market value of equity / total liabilities | 0.26 | — | 0.16 | |
| Sales / total assets | 0.05 | — | 0.05 | |
| Altman Z-score | Distress zone | −20.33 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −45.38 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| COCP Cocrystal Pharma, Inc. compare | 19.8× |
| QNTM Quantum Biopharma Ltd. compare | −0.3× |
| EVAX Evaxion A/S - Sponsored ADR compare | −4.5× |
| IMMP Prima BioMed Ltd compare | −10.5× |
| KYNB Kyntra Bio Inc | −20.3× |
| ESLA Estrella Immunopharma, Inc. compare | — |
| PLRZ Polyrizon Ltd. compare | — |
| CNTX Context Therapeutics Inc. compare | — |
| CYAD Celyad SA compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets